The CellVive® portfolio
Evidence-led innovation across cellular health
The CellVive® portfolio brings together ingredients, formulations and emerging technologies selected through the five-pillar cellular-health framework.
Our first innovations focus on cellular energy, with the platform continuing to expand into additional areas of cellular health.
CellVive NMN®
The foundation of the CellVive® platform
CellVive NMN® is Australia’s first and only nicotinamide mononucleotide ingredient permitted by the Therapeutic Goods Administration (TGA) for use in Listed Medicines.
Developed with a focus on quality, purity and scientific integrity, CellVive NMN® supports healthy cellular energy production through involvement in NAD-dependent pathways.
What is NMN?
Nicotinamide mononucleotide, or NMN, is a molecule naturally present in the body and involved in the production of NAD+.
NAD+ is an essential coenzyme involved in cellular energy metabolism and normal cellular function.
Why CellVive NMN®
| TGA-permitted | Australia’s first and only NMN ingredient permitted for use in Listed Medicines. |
|---|---|
| Pharmaceutical-grade | ≥99% purity, produced using advanced enzymatic synthesis. |
| Biotechnology manufacturing | Manufactured in partnership with SyncoZymes. |
| Evidence-led | Supported by an ongoing clinical research program in collaboration with the University of Sydney. |
| Traceable supply | Manufactured and supplied through established quality systems. |
| Built to scale | Supported by global biotechnology and Australian manufacturing partnerships. |
From science to scale
Within seven months of achieving its Australian regulatory milestone, CellVive NMN® had been adopted by more than 40 brand partners across pharmacy, health food, practitioner and direct-to-consumer channels.
More than 2.4 million products containing CellVive NMN® have since been sold.*
* Equivalent number of 30-day bottles, calculated based on 27 tonnes of CellVive NMN® supplied since December 2025.
CellVive NMN® Advance
Building on the CellVive NMN® foundation
CellVive NMN® Advance combines pharmaceutical-grade CellVive NMN® with PlexoZome® liposomal delivery technology.
The formulation brings together cellular-health science with advanced Australian formulation technology.
Advanced delivery
The effectiveness of a health formulation depends not only on the quality of its active ingredient, but also on how thoughtfully it is formulated.
CellVive NMN® Advance was developed to combine the quality and scientific foundation of CellVive NMN® with advanced delivery technology.
The formulation
-
CellVive NMN®
Australia’s first and only nicotinamide mononucleotide ingredient permitted by the TGA for use in Listed Medicines.
Supports healthy cellular energy production through involvement in NAD-dependent pathways.
-
PlexoZome®
A patented liposomal delivery technology developed by Australian biotechnology company Pharmako Biotechnologies.
PlexoZome® encapsulates active ingredients within a phospholipid structure designed to support ingredient stability and delivery.
Why CellVive NMN® Advance
-
Advanced formulation
Combines CellVive NMN® with PlexoZome® liposomal delivery technology.
-
Australian innovation
Developed in partnership with Pharmako Biotechnologies using Australian delivery technology.
-
Premium product development
Created for brands seeking a differentiated, evidence-led NMN formulation.
-
Science meets formulation
Bringing cellular-health innovation together with advanced delivery technology.
Emerging portfolio
Building beyond NMN
CellVive® was created as a cellular-health platform, not a single-ingredient proposition.
Longevity Life Sciences continues to evaluate and develop emerging ingredients and technologies across cellular energy, protection, repair, renewal and resilience.
Current areas of development include next-generation cellular-energy and cellular-renewal ingredients, including PQQ.
As scientific understanding evolves, so will the CellVive® portfolio.